102 related articles for article (PubMed ID: 7586185)
1. Human CYP2D6 gene polymorphism in Slovene cancer patients and healthy controls.
Dolzan V; Rudolf Z; Breskvar K
Carcinogenesis; 1995 Nov; 16(11):2675-8. PubMed ID: 7586185
[TBL] [Abstract][Full Text] [Related]
2. Metabolic cytochrome P450 genotypes and assessment of individual susceptibility to lung cancer.
Hirvonen A; Husgafvel-Pursiainen K; Anttila S; Karjalainen A; Sorsa M; Vainio H
Pharmacogenetics; 1992 Dec; 2(6):259-63. PubMed ID: 1306126
[TBL] [Abstract][Full Text] [Related]
3. PCR-based CYP2D6 genotyping for Finnish lung cancer patients.
Hirvonen A; Husgafvel-Pursiainen K; Anttila S; Karjalainen A; Pelkonen O; Vainio H
Pharmacogenetics; 1993 Feb; 3(1):19-27. PubMed ID: 8097947
[TBL] [Abstract][Full Text] [Related]
4. Human debrisoquine hydroxylase gene polymorphisms in cancer patients and controls.
Sugimura H; Caporaso NE; Shaw GL; Modali RV; Gonzalez FJ; Hoover RN; Resau JH; Trump BF; Weston A; Harris CC
Carcinogenesis; 1990 Sep; 11(9):1527-30. PubMed ID: 1976046
[TBL] [Abstract][Full Text] [Related]
5. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.
Evans WE; Relling MV
Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245
[TBL] [Abstract][Full Text] [Related]
6. Polymorphism in CYP1A1 and CYP2D6 genes: possible association with susceptibility to lung cancer.
Hirvonen A; Husgafvel-Pursiainen K; Anttila S; Karjalainen A; Vainio H
Environ Health Perspect; 1993 Oct; 101 Suppl 3(Suppl 3):109-12. PubMed ID: 7908263
[TBL] [Abstract][Full Text] [Related]
7. Mutant genes of cytochrome P-450IID6, glutathione S-transferase class Mu, and arylamine N-acetyltransferase in lung cancer patients.
Roots I; Brockmöller J; Drakoulis N; Loddenkemper R
Clin Investig; 1992; 70(3-4):307-19. PubMed ID: 1355678
[TBL] [Abstract][Full Text] [Related]
8. Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype.
Saxena R; Shaw GL; Relling MV; Frame JN; Moir DT; Evans WE; Caporaso N; Weiffenbach B
Hum Mol Genet; 1994 Jun; 3(6):923-6. PubMed ID: 7951238
[TBL] [Abstract][Full Text] [Related]
9. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene.
Broly F; Meyer UA
Pharmacogenetics; 1993 Jun; 3(3):123-30. PubMed ID: 8101460
[TBL] [Abstract][Full Text] [Related]
10. Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles.
Aklillu E; Persson I; Bertilsson L; Johansson I; Rodrigues F; Ingelman-Sundberg M
J Pharmacol Exp Ther; 1996 Jul; 278(1):441-6. PubMed ID: 8764380
[TBL] [Abstract][Full Text] [Related]
11. Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity.
Romkes-Sparks M; Mnuskin A; Chern HD; Persad R; Fleming C; Sibley GN; Smith P; Wilkinson GR; Branch RA
Carcinogenesis; 1994 Sep; 15(9):1955-61. PubMed ID: 7923590
[TBL] [Abstract][Full Text] [Related]
12. Genotyping of the CYP2D6 gene in Norwegian lung cancer patients and controls.
Tefre T; Daly AK; Armstrong M; Leathart JB; Idle JR; Brøgger A; Børresen AL
Pharmacogenetics; 1994 Apr; 4(2):47-57. PubMed ID: 8081413
[TBL] [Abstract][Full Text] [Related]
13. Debrisoquin oxidation genotype and susceptibility to lung cancer.
Agúndez JA; Martínez C; Ladero JM; Ledesma MC; Ramos JM; Martín R; Rodriguez A; Jara C; Benítez J
Clin Pharmacol Ther; 1994 Jan; 55(1):10-4. PubMed ID: 8299311
[TBL] [Abstract][Full Text] [Related]
14. Debrisoquine hydroxylase gene polymorphism in meningioma.
Wundrack I; Meese E; Müllenbach R; Blin N
Acta Neuropathol; 1994; 88(5):472-4. PubMed ID: 7847077
[TBL] [Abstract][Full Text] [Related]
15. Molecular genetic analysis of the cytochrome P450-debrisoquine hydroxylase locus and association with cancer susceptibility.
Smith CA; Moss JE; Gough AC; Spurr NK; Wolf CR
Environ Health Perspect; 1992 Nov; 98():107-12. PubMed ID: 1486838
[TBL] [Abstract][Full Text] [Related]
16. A missense mutation in exon 6 of the CYP2D6 gene leading to a histidine 324 to proline exchange is associated with the poor metabolizer phenotype of sparteine.
Evert B; Griese EU; Eichelbaum M
Naunyn Schmiedebergs Arch Pharmacol; 1994 Oct; 350(4):434-9. PubMed ID: 7845481
[TBL] [Abstract][Full Text] [Related]
17. Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility.
Wolf CR; Smith CA; Gough AC; Moss JE; Vallis KA; Howard G; Carey FJ; Mills K; McNee W; Carmichael J
Carcinogenesis; 1992 Jun; 13(6):1035-8. PubMed ID: 1600608
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.
Griese EU; Asante-Poku S; Ofori-Adjei D; Mikus G; Eichelbaum M
Pharmacogenetics; 1999 Dec; 9(6):715-23. PubMed ID: 10634134
[TBL] [Abstract][Full Text] [Related]
19. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene.
Kimura S; Umeno M; Skoda RC; Meyer UA; Gonzalez FJ
Am J Hum Genet; 1989 Dec; 45(6):889-904. PubMed ID: 2574001
[TBL] [Abstract][Full Text] [Related]
20. An inactive cytochrome P450 CYP2D6 allele containing a deletion and a base substitution.
Daly AK; Leathart JB; London SJ; Idle JR
Hum Genet; 1995 Mar; 95(3):337-41. PubMed ID: 7868129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
